Coya Therapeutics reported positive results from a Phase 2 trial of LD IL-2 for Alzheimer's at CTAD24. The study met primary and secondary endpoints, showing safety and efficacy. The q4wks dosing led to significant improvements in CSF Aβ42 levels.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing